The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it continues to struggle with recent challenges, an analyst said.

CVS Health (CVS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors ...

Leerink boosts CVS to a 'buy' as the healthcare-company's stock stays hot. CVS Health Corp.'s stock rose Thursday after the drugstore and healthcare-services company picked up an analyst upgrade ...

--CVS Health ® today announced two agreements that total 264,000- megawatt hours with Constellation to purchase zero-emission, renewable energy equivalent to the annual electricity use of nearly ...

CVS Health has entered into a 15-year agreement with Constellation to purchase clean, renewable energy equivalent to the energy use of 309 CVS Health locations in Illinois and Ohio.

--CVS Health ® today released the Rx Report: Transforming Community Pharmacy to Make Healthier Happen Together, which explores the ongoing evolution of community pharmacy as well as opportunities ...

CVS Health (CVS) closed the most recent trading day at $67.58, moving +1.15% from the previous trading session.

That shows the power of CVS’ market saturation; it pushed Hyrimoz through every arm of its business. CVS said the list price of Hyrimoz is 81% cheaper than brand-name Humira.

CVS Health has launched a new segment that aims to work with drugmakers to bring additional biosimilars to market.

Barclays upgrades CVS Health to Overweight, citing gains in pharmacy market share and potential upside from CostVantage. CVS is expected to recover 200 basis points in Medicare margins by 2026 ...